American Society of Ketamine Physicians, Psychotherapists, and Practitioners - 2020 ASKP Annual Conference

Tuesday, 13 October 2020 7:00 PM - Saturday, 17 October 2020 5:00 PM EST

Register Now
This event is currently not on sale. Please contact the organizer at the email address on the bottom right corner.

Registration

Sale ended

The ASKP3 Annual Conference Partial Approval - $595.00

Enter your discount code

  • Subtotal (excluding fees and discounts)
  • Fee
  • Total amount

1. Select Seats

2. Review and Proceed

Tuesday, 13 October 2020 7:00 PM - Saturday, 17 October 2020 5:00 PM EST

This is the third annual conference for the American Society of Ketamine Physicians, Psychotherapists and Practitioners.  A conference involving multi-disciplinary speakers discussing ketamine use for mood disorders, psychotherapy and pain conditions.   Please join us for this educational conference and extraordinary networking experience. 


 

 

AMERICAN SOCIETY OF KETAMINE PHYSICIANS,

PSYCHOTHERAPISTS AND PRACTITIONERS

 3rd ANNUAL MEETING

OCTOBER 13th through October 17th 

 

________________________________________________________________________________________________________________________________________ 

AGENDA

Evening Sessions

Wednesday, October 14th

 

Block 1

4:00-5:00 PST/7:00-8:00 EST

 

Room 1:         Advanced Provider Practices – “Challenges for APP’s in collaborative and independent clinic practice models” – Nykol Bailey, CRNA, Wesley Karcher, Laura Maiorana & Melissa Gabrelli

-or-

Room 2:         When Patients Stop Responding – “What to do when a patient's response to ketamine treatment decreases or stops and they have few other options” – Megan Oxley, MD

-or-

Room 3:         Nitty Gritty – “The small details for day to day operations – consenting patients, writing notes, monitoring, etc.  Bring your questions!” – Rocky Sullivan, DO & Sandhya Prashad, MD

 

Block 2

5:00-6:00 PST/8:00-9:00 EST

 

Room 1:         Advanced Provider Practices – “Challenges for APP’s in collaborative and independent clinic practice models” – Nykol Bailey, CRNA, Wesley Karcher, Laura Maiorana & Melissa Gabrelli

-or-

Room 2:         When Patients Stop Responding – “What to do when a patient's response to ketamine treatment decreases or stops and they have few other options” – Robert Grant, MD

-or-

Room 3:         Nitty Gritty – “The small details for day to day operations – consenting patients, writing notes, monitoring, etc.  Bring your questions!” – Rocky Sullivan, DO & Megan Oxley, MD


 

Thursday, October 15th

Block 1

4:00-5:00 PST/7:00-8:00 EST

 

Room 1:         Legal considerations - “A unique opportunity for participants to discuss legal considerations with a lawyer well educated in ketamine clinics.” – Cindy Van Praag, MD & Daniel Sternthal, Esq.

-or-

Room 2:         Beginner KAP - “How to introduce KAP into your practice for improved patient outcomes.” – Robert Grant, MD & Jessica Katzman, PsyD

-or-

Room 3:         Pain protocols - “Applying consensus guidelines to treat chronic pain with ketamine in the outpatient setting” – Steven Mandel, MD & Megan Oxley, MD

 

Block 2

5:00-6:00 PST/8:00-9:00 EST

 

Room 1:         Legal considerations - “A unique opportunity for participants to discuss legal considerations with a lawyer well educated in ketamine clinics.” – Cindy Van Praag, MD & Daniel Sternthal, Esq.

-or-

Room 2:         Advanced KAP - “Ask experts on how to best use KAP to best help your most challenging cases.” – Will Van Derveer, MD

-or-

Room 3:         Pain protocols - “Applying consensus guidelines to treat chronic pain with ketamine in the outpatient setting” – Steven Mandel, MD & Megan Oxley, MD

 


 

Friday, October 16th

 

8:00a – 8:30a PT/11:00a-11:30a ET

State of the ASKP3 Union

·         Welcome, Recap of 2020 

·         Standards & Ethics Presentation 

 

8:30a-10:00a PST/11:30a-1:00p EST

Live Lecture Block 1

·         Jason Wallach, PhD,– The Neuropharmacology of Ketamine

·         Sagar Parikh, MD, FRCPC – Comparison of Different Duration Regimens for Intravenous Racemic Ketamine: 100-Minute Versus 40-Minute Infusions for Refractory Depression

 

10:00a-11:00a PST/1:00p-2:00p EST

Social Hour – Specialty Based Small Chat Rooms - Zoom

·         Anesthesia

·         Psychiatry

·         Emergency Medicine

·         IM/FM

·         Psychotherapy

·         Advanced Providers

 

11:00a-1:00p PST/2p-4p EST

Live Lecture Block 2

·         Ravi Das. MD – Destabilization of Maladaptive Drinking Memories Combined With Ketamine Effectively Reduced the Reinforcing Effects of Alcohol and Long-term Drinking Levels

·         Sandhya Prashad, MD - The Use of Intranasal Esketamine Alongside Intravenous Ketamine in Clinical Practice

·         Tiago Gil, MD - Ketamine is a Common Drug for Depression and Epilepsy. Is There a Shared Pathophysiology?

 

1:00p-2:00p PST/4:00p-5:00p EST

Social Hour – Location Based Small Chat Rooms

·         Pacific Northwest

·         West Coast

·         Midwest

·         South East

·         North East

 

2:00p-4:00p PST/5:00p-7:00p EST

Live Lecture Block 3

·         Will Van Derveer, MD – Suicidality and Inflammation: Improving and Extending Ketamine’s Efficacy

·         Megan Oxley, MD – A Safe Approach to at Home Ketamine

 

Saturday, October 17th

 

8:00a-10:00a PST/11:00a-1:00p EST

Live Lecture Block 4

·         James Murrough, MD, PhD - Discovering New Targets for the Treatment of Depression: Insights from Ketamine and Beyond

·         Rupert McShane, MD – Understanding the Advantages and Disadvantages of Prescribing Ketamine Through Different Routes of Administration

 

10:00a-11:00a PST/1:00p-2:00p EST

Social Hour – Small Chat Rooms based on Interest

·         Psychedelics

·         Esketamine

·         New Clinic

·         KAP

·         TMS+K

 

11:00a-1:00p PST/2:00p-4:00p EST
Live Lecture Block  5

·         Raquel Bennett, PsyD - Paradigms of Ketamine Treatment

-Common Mistakes in Ketamine Treatment for Mood Disorders

·         Gita Vaid, MD - Ketamine as an Agent for Transformation

 

1:00p-2:00p PST/4:00p-5:00p EST

Conference Close

·         Meet your New Board Members

·         Closing Remarks

·         2021 Conference Announcement  

American Society of Ketamine Physicians, Psychotherapists & Practition

www.askp.org

The American Society of Ketamine Physicians, Psychotherapists, and Practitioners is a group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions. To get involved or apply for membership, please visit www.askp.org

Contact the Organizer

Learn more aboutRaquel Bennett, Psy.D. Raquel Bennett, Psy.D.
Raquel Bennett, Psy.D.
Psychologist and Ketamine Specialist
KRIYA

Raquel Bennett, Psy.D. is a psychologist and ketamine specialist from Berkeley, California. She primarily works with people who are living with severe depression, bipolar disorder, and/or suicidal ideation. Dr. Bennett is fascinated by the antidepressant and anti-suicidal properties of ketamine, and has been studying them since 2002. She also has a long-standing interest in the psychedelic and mystical properties of ketamine, and the potential for this medicine to be used for spiritual exploration. Dr. Bennett is the founder of KRIYA Institute and KRIYA Conference, which are both devoted to the use of ketamine in psychiatry and psychotherapy. You can learn more about her work at www.kriyainstitute.com.

www.kriyainstitute.com

About Raquel Bennett, Psy.D.

Psychologist and Ketamine Specialist
KRIYA
Learn more aboutJames Murrough, MD, PhD James Murrough, MD, PhD
James Murrough, MD, PhD
Associate Professor
Icahn School of Medicine at Mount Sinai

Dr. James Murrough is Associate Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. He is a Faculty member of the Friedman Brain Institute and a Primary Principal Investigator of the Center of Excellence in Neuropharmacology, both components of the Icahn School of Medicine. Dr. Murrough conducts clinical and translational research aimed at understanding the biological basis of mood and anxiety disorders in order to point the way towards new, more effective treatments. He received his Bachelor of Science in Neuroscience and Behavioral Biology from Emory University in Atlanta and his Medical degree from Tufts University School of Medicine in Boston. He completed his residency training in Psychiatry at Mount Sinai and a research fellowship in experimental therapeutics and clinical neuroscience in mood disorders, also at Mount Sinai. He obtained a PhD in clinical research methodology and biostatistics from Mount Sinai as part of a Career Development Award from the National Institute of Mental Health. Dr. Murrough has received research support from the National Institutes of Health, the Doris Duke Charitable Foundation, the American Foundation for Suicide Prevention, the Dana Foundation and the Brain and Behavior Research Foundation. He is a Member of the American College of Neuropsychopharmacology and an active member of the scientific community. In addition to his research and educational activities, Dr. Murrough maintains an active clinical practice focusing on evidence-based pharmacological treatments for mood and anxiety disorders.

https://icahn.mssm.edu/profiles/james-murrough

About James Murrough, MD, PhD

Associate Professor
Icahn School of Medicine at Mount Sinai
Learn more aboutGita Vaid, MD Gita Vaid, MD
Gita Vaid, MD
Psychiatrist
The Ketamine Training Center

Gita Vaid, MD is a Board Certified Psychiatrist and psychoanalyst practicing in New York City. Dr Vaid completed her residency training at NYU Medical Center and psychoanalytic training at the Institute for Psychoanalytic Education affiliated with NYU. She has a rich research and biological background, completing a fellowship in clinical psychopharmacology and neurophysiology at New York Medical College and a research fellowship at NYU Medical Center. Dr Vaid is currently on faculty and teaches at both IPE and the NYU department of Psychiatry. She has a special interest in teaching interview technique, psychoanalytic theory and British object relations. Dr Vaid’s current focus and interest is in psychedelic assisted psychotherapy. She is a MAPS training therapist and part of the NY site Phase 3 MDMA psychotherapy study for PTSD. She trained with Phil Wolfson MD with KAP and has been using it in clinical practice while developing psychotherapy models to reimagine how psychotherapy is practiced and might be blended with various complementary modalities.

https://theketaminetrainingcenter.com/

About Gita Vaid, MD

Psychiatrist
The Ketamine Training Center
Learn more aboutMegan Oxley, MD Megan Oxley, MD
Megan Oxley, MD
Vice President, American Society of Ketamine Physicians, Psychotherapists & Practitioners, Founder and Medical Director of Michigan Progressive Health
Michigan Progressive Health

Dr. Megan Oxley is the founder and medical director of Michigan Progressive Health. A Board Certified Emergency Medicine physician, Dr. Oxley graduated from prestigious Wayne State University in 2009. She completed her residency training in Emergency Medicine in Detroit, serving the inner city. She spent a decade working in emergency departments in Michigan and Maryland. While researching options to help a family member with treatment resistant depression, she discovered the immense benefit that ketamine can have in chronic mood and pain conditions. Dedicated to providing this service to as many as possible, she established Michigan Progressive Health, an integrative ketamine infusion clinic in Royal Oak Michigan. Dr. Oxley has been providing ketamine infusions for over four years. She is a founding board member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners and is the current Vice President. One of Dr. Oxley’s passions is to educate the public on the use of ketamine in treating mood disorders and other ailments. She has organized the ASKP3 conferences for the last three years and has been a speaker for the previous two ASKP3 conferences. She has lectured at several major universities in Michigan to both medical students and psychiatry residents to help expand education and awareness of this rapidly evolving therapeutic modality. In addition, Dr. Oxley is currently participating in a year long integrative psychiatry fellowship with the Integrative Psychiatry Institute. Dr. Oxley has a special interest in using ketamine and future psychedelic medicines to help patients reduce their need on conventional psychiatric medications and improve their overall health.

https://michiganprogressivehealth.com/

About Megan Oxley, MD

Vice President, American Society of Ketamine Physicians, Psychotherapists & Practitioners, Founder and Medical Director of Michigan Progressive Health
Michigan Progressive Health
Learn more aboutSandhya Prashad, MD Sandhya Prashad, MD
Sandhya Prashad, MD
President, American Society of Ketamine Physicians, Psychotherapists & Practitioners, Founder and Medical Director of Houstone Ketamine Therapeutics and Houston TMS Therapeutics
Houston Ketamine Therapeutics

Sandhya Prashad, MD is a board-certified psychiatrist and is the founder and medical director of Houston Ketamine Therapeutics and Houston TMS Therapeutics. Dr. Prashad completed both medical school and residency training at Baylor College of Medicine in Houston, Texas. She completed her undergraduate training at the University of Texas in Austin. During her residency training, she served as the administrative chief resident as well as the chief resident of the Baylor Psychiatry Clinic. She has a special interest in treating depression and bipolar disorder, especially those that are treatment resistant. During her residency training, she focused on evaluating and treating treatment resistant mood disorders at the Baylor Mood Disorders Center. Dr. Prashad has been in private practice in the Houston area since 2011. She has been administrating IV Ketamine in her practice since 2016 and is also a founding member, the former secretary and the current president of the American Society of Ketamine Physicians, Psychotherapists and Practitioners. She also utilizes deep TMS and esketamine in her practice for treating treatment resistant disorders. Dr. Prashad is also actively involved in providing awareness and education to other physicians and the public regarding the benefits of ketamine therapy. She has presented on the national level at several medical conferences regarding the use of ketamine. In addition, she has served on an advisory panel for research regarding ketamine.

http://houstonketaminetherapy.com/

About Sandhya Prashad, MD

President, American Society of Ketamine Physicians, Psychotherapists & Practitioners, Founder and Medical Director of Houstone Ketamine Therapeutics and Houston TMS Therapeutics
Houston Ketamine Therapeutics
Learn more aboutRupert McShane, MD Rupert McShane, MD
Rupert McShane, MD
Associate Professor, Department of Psychiatry, Oxfordshire ECT
Oxfordshire ECT

Dr. Rupert McShane is interested in treatment-resistant depression and dementia. Clinically, he leads the Oxfordshire ECT and ketamine services and run a memory clinic. His main focus is developing policy and monitoring arrangements for rapidly acting antidepressants such as ketamine. In March of 2018, Dr. McShane led the international academic conference on Ketamine and Related Compounds for Psychiatric Disorders. He works on ways of optimizing the effects of ketamine and he is a local PI for trials of rapidly acting antidepressants. Following an NIHR-funded case series exploring the use of repeated ketamine for resistant depression, they have now treated over 200 patients and are continuing to refine treatment protocols. Dr. McShane led a qualitative study of ECT, which led to the creation of a Health talk module of patients talking about their experience and an exploration of why experiences are so polarized. His main current focus is the development of a monitoring system to support prescribers and patients to manage the rare but inevitable and potentially highly destructive risks of doctor shopping, switching and dose escalation

https://www.psych.ox.ac.uk/team/rupert-mcshane

About Rupert McShane, MD

Associate Professor, Department of Psychiatry, Oxfordshire ECT
Oxfordshire ECT
Learn more aboutJason Wallach, PhD Jason Wallach, PhD
Jason Wallach, PhD
Associate Professor, University of the Sciences
University of the Sciences

Dr. Jason Wallach is an Associate Professor at the University of the Sciences. He teaches courses in Laboratory Biomethods, Pharmacology and Toxicology Laboratory Techniques, Psychopharmacology, Pathology, Simulated Physiology Labs and Toxicology. Dr. Wallach also has an appointment to the Substance Use Disorders Institute where he is interested in medical cannabis and curriculum development for substance use disorder education. Dr. Wallach’s research focuses on the analytical and pharmacological characterizations of psychoactive drugs focusing on synthetic psychoactive drugs (SPDs) and “legal highs”. Dr. Wallach also conducts research in drug development for several therapeutic areas including neuropathic pain, neurodegenerative disease, depression, and cancer. This work includes investigations of structure activity relationships, drug tolerability, target selectivity and multi-target drug design, and biased ligand development. Dr. Wallach received his Bachelor of Science in Cell and Molecular Biology at Indiana University of Pennsylvania and his PhD in Pharmacology and Toxicology at the University of the Sciences.

https://faculty.usciences.edu/faculty/wallach-jason

About Jason Wallach, PhD

Associate Professor, University of the Sciences
University of the Sciences
Learn more aboutSagar V. Parikh, MD, FRCPC Sagar V. Parikh, MD, FRCPC
Sagar V. Parikh, MD, FRCPC
John F. Greden Professor of Depression and Clinical Neuroscience Professor of Psychiatry Associate Director, University of Michigan Depression Center
University of Michigan Depression Center

Dr. Sagar Parikh was appointed as the John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of Psychiatry, at the University of Michigan in March 2015. He was also designated as an Associate Director of the Michigan Comprehensive Depression Center. Dr. Parikh is also adjunct Professor of Psychiatry at the University of Toronto, where he was on staff full-time from 1994-2015. Dr. Parikh is the author / editor of two books and over 150 peer-reviewed articles and book chapters, and co-author of CANMAT(link is external) treatment guidelines for depression and for bipolar disorder, the world’s most cited mood disorder guidelines. He holds research grants from multiple funding agencies, covering studies in clinical treatments in mood disorders, health services research, genetics, epidemiology, and educational research. He has conducted clinical trials looking at the combination of medication and psychotherapy for bipolar disorder and for depression, as well as pharmacotherapy trials in mood disorders. Current major projects include a multi-site study of Biomarkers in Major Depression, Functional / Cognitive Remediation for Bipolar Disorder and Depression, Workplace Depression Interventions, a RCT of pharmacogenomic testing to aid treatment of depression, and a RCT of telephone-delivered CBT for bariatric surgery patients. As medical director of Mensante, he helped create a novel internet system for recognition and management of mental disorders that is commercially marketed. Dr. Parikh serves as Secretary of the International Society for Affective Disorders(link is external), and Co-Head, Section of Affective Disorders, World Psychiatric Association(link is external); Medical Director, National Network of Depression Centers(link is external) (USA); and Education Chair, CANMAT(link is external) (Canadian Network for Mood and Anxiety Treatments). He is the recipient of multiple awards for research, teaching, and service.

https://medicine.umich.edu/dept/prechter-program/sagar-v-parikh-md-frcpc

About Sagar V. Parikh, MD, FRCPC

John F. Greden Professor of Depression and Clinical Neuroscience Professor of Psychiatry Associate Director, University of Michigan Depression Center
University of Michigan Depression Center
Learn more aboutRavi Das, BSC, MSC, PhD Ravi Das, BSC, MSC, PhD
Ravi Das, BSC, MSC, PhD
Associate Professor, Educational Psychology Research Methods and Statistics University College London
University College London

Dr. Ravi Das is a researching psychopharmacologist based in the sub-department of Clinical, Educational and Health Psychology and lecturer in Research Methods and Statistics on the DEdPsy and DECPsy courses. Dr. Das studied for his BSc in Psychology, and MSc in cognitive neuroscience at UCL before completing his PhD in Psychopharmacology in the UCL Clinical Psychopharmacology Unit. Dr. Das’s research takes a translational and experimental medicine approach, with the aim of developing more effective treatments for addictions and anxiety disorders. Primarily, Dr. Das focuses on the mechanisms of memory plasticity, how these are involved in the development of addictive and anxiety disorders and how they can be leveraged using drug or behavioral interventions for clinical benefit. Dr. Das is interested in the neuroscience, psychology and pharmacology of memory reconsolidation; the process whereby established memories become briefly unstable when retrieved before being re-stored in an updated form. By targeting memories while they are unstable, it is theoretically possible to modify the maladaptive memories that underpin cravings and relapse in addiction, fear in anxiety disorders or flashbacks in PTSD. Dr. Das’s other research interests include the phenomenology and effects of illicit drug use, and cognitive and mindfulness-based strategies in substance use disorders.

https://www.ucl.ac.uk/pals/people/ravi-das

About Ravi Das, BSC, MSC, PhD

Associate Professor, Educational Psychology Research Methods and Statistics University College London
University College London
Learn more aboutWill Van Derveer, MD Will Van Derveer, MD
Will Van Derveer, MD
Psychiatrist
Integrative Psychiatric Healing Center

Will Van Derveer, MD is a psychiatrist and psychotherapist with several years of experience participating in indigenous shamanic medicine ceremonies abroad. He has facilitated integration for retreat participants during and after retreats with Gabor Mate MD. Dr. Van Derveer is a study physician and psychotherapist on multiple MAPS clinical trials, evaluating MDMA psychotherapy for PTSD. In this context, he has provided study subjects preparation and integration sessions as well as MDMA psychotherapy. He has practiced integrative psychiatry in Boulder, CO since 2002, and teaches psychiatric providers and psychiatry trainees how to heal people without relying solely on medications.

https://psychiatryinstitute.com/podcast/integrative-psychiatry-new-understanding-mental-illness-human-potential-hpp-07/

About Will Van Derveer, MD

Psychiatrist
Integrative Psychiatric Healing Center

Comments